NCT03761901 - Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium | Biotech Hunter

Enrollment

141

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

June 19, 2019

Study Completion Date

June 19, 2019

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

1L treatment

chemotherapy, EGFR TKI, immunotherapy, other

DRUG

2L Treatment

Chemotherapy, EGFR TKI, immunotherapy, other

DRUG

3L treatment

chemotherapy, EGFR TKI, immunotherapy, other

Trial Locations (15)

1090

Research Site, Brussels

1200

Research Site, Brussels

2020

Research Site, Antwerp

2300

Research Site, Turnhout

2650

Research Site, Edegem

2800

Research Site, Mechelen

3500

Research Site, Hasselt

3800

Research Site, Sint-Truiden

5004

Research Site, Bouge

5530

Research Site, Yvoir

6000

Research Site, Charleroi

7000

Research Site, Mons

8800

Research Site, Roeselare

9000

Research Site, Ghent

9100

Research Site, Sint-Niklaas